HealthEdge Announces Successful Sale of LifeSync to Amphenol

Whats Happening:

HealthEdge Investment Partners has completed the sale of LifeSync, a developer and manufacturer of patient monitoring devices, to Amphenol. The fund grew LifeSync's revenues from $5 million to approximately $100 million through strategic acquisitions, management changes, and operational improvements.

Key Moves:

• HealthEdge completes sale of LifeSync to Amphenol

• LifeSync's revenues grew from $5 million to $100 million under HealthEdge's ownership

• HealthEdge implemented new management and completed four acquisitions for LifeSync

By The Numbers:

• LifeSync's revenue grew from $5 million to approximately $100 million

• HealthEdge completed four acquisitions for LifeSync

• HealthEdge partners have over 100 years of combined healthcare experience

Key Quotes:

• "When we first invested in LifeSync, our objective was to grow revenues and scale an entrepreneurial business with a great product and unique IP," said Brian Anderson, Managing Partner of HealthEdge.

• "I am proud of the growth LifeSync has accomplished and the work our global team does each day to provide critical medical products to hospitals," added Bob Buehler, General Manager of LifeSync.

Bottom Line:

HealthEdge's successful exit from LifeSync demonstrates the fund's ability to create significant value in the healthcare sector. By implementing strategic changes and driving growth, HealthEdge transformed LifeSync from a $5 million revenue company to a $100 million enterprise, resulting in strong investment returns for HealthEdge Fund II.

Read Full Article